Free Newsletter
Alzheimer’s vax eliminated plaque, not dementia
Researchers are trying to find out why a vaccine for Alzheimer's would be able to eliminate the beta-amyloid plaque long considered responsible for the disease without actually curing the disease. British scientists tracked patients in the vaccine study for years and performed autopsies on seven volunteers who died during the study. Nearly all the beta-amyloid had been eliminated, but all of the patients suffered severe dementia at the time of their death.
"It may be that these toxic plaques trigger the neurodegeneration, but don't have an ongoing role," said Clive Holmes of the University of Southampton, lead author.
For other experts in the field, though, the outcome helped to underscore how little researchers understand Alzheimer's. And some say the research target should shift to tau, another brain protein that some believe would make a better target.
- read the AP report
Related Articles:
Big pharma sees big payback for Alzheimer's research
Dimebon shows positive data in Alzheimer's study
Alzheimer's vaccine spurs immune response in mice
Genetic engineering ‘vacuums' Alzheimer plaque
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




